154 related articles for article (PubMed ID: 15212616)
1. Targeting Syk as a treatment for allergic and autoimmune disorders.
Wong BR; Grossbard EB; Payan DG; Masuda ES
Expert Opin Investig Drugs; 2004 Jul; 13(7):743-62. PubMed ID: 15212616
[TBL] [Abstract][Full Text] [Related]
2. TAS05567, a Novel Potent and Selective Spleen Tyrosine Kinase Inhibitor, Abrogates Immunoglobulin-Mediated Autoimmune and Allergic Reactions in Rodent Models.
Hayashi H; Kaneko R; Demizu S; Akasaka D; Tayama M; Harada T; Irie H; Ogino Y; Fujino N; Sasaki E
J Pharmacol Exp Ther; 2018 Jul; 366(1):84-95. PubMed ID: 29728446
[TBL] [Abstract][Full Text] [Related]
3. Syk kinase inhibitors in allergic diseases.
Denyer J; Patel V
Drug News Perspect; 2009 Apr; 22(3):146-50. PubMed ID: 19440557
[TBL] [Abstract][Full Text] [Related]
4. Inhibitors of switch kinase 'spleen tyrosine kinase' in inflammation and immune-mediated disorders: a review.
Kaur M; Singh M; Silakari O
Eur J Med Chem; 2013 Sep; 67():434-46. PubMed ID: 23917087
[TBL] [Abstract][Full Text] [Related]
5. Homoisoflavanone prevents mast cell activation and allergic responses by inhibition of Syk signaling pathway.
Lee YS; Hur S; Kim TY
Allergy; 2014 Apr; 69(4):453-62. PubMed ID: 24446972
[TBL] [Abstract][Full Text] [Related]
6. Piceatannol is an effective inhibitor of IgE-mediated secretion from human basophils but is neither selective for this receptor nor acts on syk kinase at concentrations where mediator release inhibition occurs.
Miura K; Lavens-Phillips S; MacGlashan DW
Clin Exp Allergy; 2001 Nov; 31(11):1732-9. PubMed ID: 11696049
[TBL] [Abstract][Full Text] [Related]
7. Critical role for the tyrosine kinase Syk in signalling through the high affinity IgE receptor of mast cells.
Costello PS; Turner M; Walters AE; Cunningham CN; Bauer PH; Downward J; Tybulewicz VL
Oncogene; 1996 Dec; 13(12):2595-605. PubMed ID: 9000133
[TBL] [Abstract][Full Text] [Related]
8. Curcumin, a constituent of curry, suppresses IgE-mediated allergic response and mast cell activation at the level of Syk.
Lee JH; Kim JW; Ko NY; Mun SH; Her E; Kim BK; Han JW; Lee HY; Beaven MA; Kim YM; Choi WS
J Allergy Clin Immunol; 2008 May; 121(5):1225-31. PubMed ID: 18394691
[TBL] [Abstract][Full Text] [Related]
9. Syk-kinase inhibition prevents mast cell activation in nasal polyps.
Patou J; Holtappels G; Affleck K; van Cauwenberge P; Bachert C
Rhinology; 2011 Mar; 49(1):100-6. PubMed ID: 21468383
[TBL] [Abstract][Full Text] [Related]
10. Syk kinase as a treatment target for therapy in autoimmune diseases.
Kyttaris VC; Tsokos GC
Clin Immunol; 2007 Sep; 124(3):235-7. PubMed ID: 17662659
[TBL] [Abstract][Full Text] [Related]
11. Syk inhibitors as treatment for allergic rhinitis.
Masuda ES; Schmitz J
Pulm Pharmacol Ther; 2008; 21(3):461-7. PubMed ID: 17669674
[TBL] [Abstract][Full Text] [Related]
12. A novel druglike spleen tyrosine kinase binder prevents anaphylactic shock when administered orally.
Mazuc E; Villoutreix BO; Malbec O; Roumier T; Fleury S; Leonetti JP; Dombrowicz D; Daëron M; Martineau P; Dariavach P
J Allergy Clin Immunol; 2008 Jul; 122(1):188-94, 194.e1-3. PubMed ID: 18539317
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic prospect of Syk inhibitors.
Ruzza P; Biondi B; Calderan A
Expert Opin Ther Pat; 2009 Oct; 19(10):1361-76. PubMed ID: 19670961
[TBL] [Abstract][Full Text] [Related]
14. Antisense oligonucleotides to Syk kinase: a novel therapeutic approach for respiratory disorders.
Ulanova M; Puttagunta L; Kim MK; Schreiber AD; Befus AD
Curr Opin Investig Drugs; 2003 May; 4(5):552-5. PubMed ID: 12833648
[TBL] [Abstract][Full Text] [Related]
15. Spleen tyrosine kinase inhibition in the treatment of autoimmune, allergic and autoinflammatory diseases.
Pamuk ON; Tsokos GC
Arthritis Res Ther; 2010; 12(6):222. PubMed ID: 21211067
[TBL] [Abstract][Full Text] [Related]
16. Identification of the Syk kinase inhibitor R112 by a human mast cell screen.
Rossi AB; Herlaar E; Braselmann S; Huynh S; Taylor V; Frances R; Issakani SD; Argade A; Singh R; Payan DG; Masuda ES
J Allergy Clin Immunol; 2006 Sep; 118(3):749-55. PubMed ID: 16950297
[TBL] [Abstract][Full Text] [Related]
17. Preclinical Pharmacology Characterization of Sovleplenib (HMPL-523), an Orally Available Syk Inhibitor.
Cai Y; He J; Wu Z; He W; Dai X; Xu Y; Cheng M; Yang N; Ren Y; Wang G; Wang J; Sai Y; Jia H; Dai G; Li X; Su W
J Pharmacol Exp Ther; 2024 Jan; 388(1):156-170. PubMed ID: 37918855
[TBL] [Abstract][Full Text] [Related]
18. Protein tyrosine kinase Syk in mast cell signaling.
Siraganian RP; Zhang J; Suzuki K; Sada K
Mol Immunol; 2002 Sep; 38(16-18):1229-33. PubMed ID: 12217388
[TBL] [Abstract][Full Text] [Related]
19. Spleen tyrosine kinase (Syk) as a novel target for allergic asthma and rhinitis.
Ulanova M; Duta F; Puttagunta L; Schreiber AD; Befus AD
Expert Opin Ther Targets; 2005 Oct; 9(5):901-21. PubMed ID: 16185147
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of allergic inflammation in the airways using aerosolized antisense to Syk kinase.
Stenton GR; Ulanova M; Déry RE; Merani S; Kim MK; Gilchrist M; Puttagunta L; Musat-Marcu S; James D; Schreiber AD; Befus AD
J Immunol; 2002 Jul; 169(2):1028-36. PubMed ID: 12097411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
